BACKGROUND: There have been many randomised trials of adjuvant prolonged
polychemotherapy among women with early breast cancer, and an updated overview of …

Cytotoxic chemotherapy remains the mainstay of treatment for triple-negative breast cancer
(TNBC) despite the promise of new targeted and biologic agents. Many studies have shown …

Purpose The 21-gene recurrence score (RS) assay quantifies the likelihood of distant
recurrence in women with estrogen receptor–positive, lymph node–negative breast cancer …

PURPOSE: To assess patient and tumor characteristics associated with a complete
pathologic response (pCR) in both the breast and axillary lymph node specimens and the …

Purpose: The National Surgical Adjuvant Breast and Bowel Project Protocol B-27 was
designed to determine the effect of adding docetaxel after four cycles of preoperative …

Background The status of human epidermal growth factor receptor type 2 (HER2) in breast-
cancer cells predicts clinical outcomes in women who receive adjuvant anthracycline-based …

Purpose We sought to identify gene expression markers that predict the likelihood of
chemotherapy response. We also tested whether chemotherapy response is correlated with …

Estrogen and progesterone receptors (ER and PR) have now been studied in clinical breast
cancer for more than 20 years. Positive receptor status correlates with favorable prognostic …

Studies of new prognostic factors form an extensive part of the literature of oncology. Recent
examples published in this journal include studies of patients with primary cerebral …

Summary Background Findings from the National Surgical Adjuvant Breast and Bowel
Project B-14 and B-20 trials showed that tamoxifen benefited women with oestrogen …